

What is claimed is:

1. A method of treating cancer selected from the group consisting of adenocarcinoma and leukemia comprising administering to a human a composition comprising a therapeutically effective amount of a hapten modified syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell.

2. The method of claim 1 wherein said adenocarcinoma is selected from ovarian carcinoma and colon carcinoma.

3. The method of claim 1 wherein said leukemia is acute myelogenous leukemia.

4. The method of claims 1 wherein said tumor cells are autologous.

5. The method of claims 1 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, phosphorylcholine, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

6. The method of claims 1 wherein said hapten is dinitrophenyl.

7. The method of claims 1 wherein said composition is mixed with an immunological adjuvant prior to administration.

8. The method of claim 7 wherein said immunological adjuvant is Bacille

Calmette-Guerin.

9. A method of eliciting T lymphocytes to infiltrate a tumor of a human comprising administering to said human a composition comprising a therapeutically effective amount of a hapten modified syngeneic human tumor cell substantially in a no growth phase and an . adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said T lymphocytes that infiltrate said tumor of said human, wherein said tumor is selected from the group consisting of adenocarcinoma and leukemia.

10. A method of eliciting an inflammatory immune response to a tumor of a human comprising administering to said human a composition comprising a therapeutically effective amount of a hapten modified syngeneic, human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said inflammatory immune response, wherein said tumor is selected from the group consisting of adenocarcinoma and leukemia.

11. A method of eliciting a delayed-type hypersensitivity response to a tumor of a human comprising administering to said human a composition comprising a therapeutically effective amount of a hapten modified syngeneic human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said delayed-type hypersensitivity response, wherein said tumor is selected from the group consisting of adenocarcinoma. and leukemia.

12. A composition for treating cancer selected from the group consisting of adenocarcinoma and leukemia comprising a therapeutically effective amount of a hapten modified syngeneic human tumor cell substantially in a no growth phase and an adjuvant for

administration to a human, wherein said human suffers from a malignant tumor of the same type as said tumor cell.

13. The composition of claim 11 wherein said adenocarcinoma is selected from ovarian carcinoma and colon carcinoma.

14. The composition of claim 11 wherein said leukemia is acute myelogenous leukemia.

15. The composition of claim 11 wherein said tumor cells are autologous.

16. The composition of claim 11 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, phosphorylcholine, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

17. The composition of claim 11 wherein said hapten is dinitrophenyl.

18. The composition of claim 11 wherein said immunological adjuvant is *Bacille Calmette-Guerin*.

19. A composition comprising a hapten modified syngeneic human tumor cell, said hapten modified tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human, wherein said tumor is selected from the group consisting of adenocarcinoma and leukemia.

1 20. A composition comprising a hapten modified syngeneic human tumor
2 cell, said hapten modified tumor cell substantially in a no growth phase and having the
3 property, when administered with an adjuvant to a human suffering from a malignant tumor
4 of the same type as said tumor cell, of eliciting an inflammatory immune response against
5 the tumor of said human, wherein said tumor is selected from the group consisting of
6 adenocarcinoma and leukemia.

1 21. A composition comprising a hapten modified syngeneic human tumor
2 cell, said hapten modified tumor cell substantially in a no growth phase and having the
3 property, when administered with an adjuvant to a human suffering from a malignant tumor
4 of the same type as said tumor cell, of eliciting a delayed-type hypersensitivity response to
5 the tumor of said human, wherein said tumor is selected from the group consisting of
6 adenocarcinoma and leukemia.

10025195-121901